Glaukos’ iStent inject® Delivers Greater IOP Reduction vs. iStent® According to Newly Published Case Series
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that an independent, international case series published in Ophthalmology and Therapy showed that iStent inject® Trabecular Micro-Bypass System achieved a greater absolute intraocular pressure (IOP) reduction and a higher medication-free rate at one ye